(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
局所進行性、切除不能、または転移性消化管間質腫瘍を有する被験者における CGT9486 + スニチニブ対スニチニブの第 3 相無作為化非盲検多施設臨床試験
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Cogent Biosciences
- 電話番号:617-945-5576
- メール:peakinfo@cogentbio.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35249
- 引きこもった
- University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale、Arizona、アメリカ、85259
- 募集
- Mayo Clinic
-
Tucson、Arizona、アメリカ、85719
- 積極的、募集していない
- University of Arizona- Cancer Center
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope
-
Los Angeles、California、アメリカ、90404
- 積極的、募集していない
- University of California, Los Angeles (UCLA)
-
San Diego、California、アメリカ、92093
- 募集
- University of California, San Diego (UCSD)
-
San Francisco、California、アメリカ、94158
- 積極的、募集していない
- University of California, San Francisco
-
-
Colorado
-
Denver、Colorado、アメリカ、80204
- 募集
- University of Colorado Denver
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- 募集
- MedStar Washington Hospital Center
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- Mayo Clinic Jacksonville
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orange City、Florida、アメリカ、32763
- 引きこもった
- Mid Florida Hematology and Oncology Center
-
Orlando、Florida、アメリカ、32806
- 募集
- Orlando Health Cancer Institute
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern University
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa Hospital and Clinics
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 積極的、募集していない
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- 募集
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
-
Missouri
-
St Louis、Missouri、アメリカ、63130
- 募集
- Washington University
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- 募集
- Nebraska Methodist Hospital
-
-
New York
-
Buffalo、New York、アメリカ、14203
- 積極的、募集していない
- Roswell Park Comprehensive Cancer Center
-
New York、New York、アメリカ、10021
- 募集
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27705
- 募集
- Duke University
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- 募集
- The Cleveland Clinic Foundation
-
Columbus、Ohio、アメリカ、43210
- 募集
- The Ohio State University Comprehensive Cancer Center
-
Toledo、Ohio、アメリカ、43614
- 引きこもった
- University of Toledo Medical Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- 募集
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19111
- 募集
- Fox Chase Cancer Center
-
Pittsburgh、Pennsylvania、アメリカ、15232
- 募集
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37920
- 引きこもった
- University of Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University Medical Center
-
-
Texas
-
Houston、Texas、アメリカ、77030-4009
- 募集
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 積極的、募集していない
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53705
- 募集
- University of Wisconsin - Carbone Cancer Center
-
-
-
-
-
Buenos Aires、アルゼンチン、C1426ANZ
- 積極的、募集していない
- Instituto Alexander Fleming
-
Córdoba、アルゼンチン、X5000HWE
- 積極的、募集していない
- Instituto Oncologico de Cordoba (IONC)
-
-
-
-
-
Cambridge、イギリス、CB2 0QQ
- 積極的、募集していない
- Cambridge Addenbrooke's Hospital
-
Glasgow、イギリス、G12 0YN
- 引きこもった
- Beatson, West of Scotland Cancer Centre
-
London、イギリス、NW1 2PG
- 積極的、募集していない
- University College London Hospital
-
London、イギリス、SW3 6JJ
- 積極的、募集していない
- Royal Marsden Hospital - Surrey
-
London、イギリス、SE1 9RT
- 引きこもった
- Guy's Hospital
-
Manchester、イギリス、M20 4BX
- 積極的、募集していない
- The Christie NHS Foundation Trust
-
Sheffield、イギリス、S10 2SJ
- 積極的、募集していない
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Aviano、イタリア、33081
- 積極的、募集していない
- Centro Riferimento Oncologico - Aviano
-
Bologna、イタリア、40138
- 積極的、募集していない
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
-
Brescia、イタリア、25123
- 積極的、募集していない
- ASST degli Spedali Civili di Brescia
-
Candiolo、イタリア、10060
- 引きこもった
- IRCCS La Fondazione e l'Istituto di Candiolo
-
Florence、イタリア、50134
- 積極的、募集していない
- Azienda Ospedaliero-Universitaria Careggi
-
Meldola、イタリア、47014
- 積極的、募集していない
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
-
Milan、イタリア、20133
- 積極的、募集していない
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan、イタリア、20141
- 積極的、募集していない
- Istituto Europeo di Oncologia
-
Palermo、イタリア、90127
- 積極的、募集していない
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Roma、イタリア、00128
- 積極的、募集していない
- Policlinico Universitario Campus Bio-Medico
-
Rozzano、イタリア、20089
- 積極的、募集していない
- Istituto Clinico Humanitas
-
Verona、イタリア、31726
- 積極的、募集していない
- Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
-
-
-
-
-
Amsterdam、オランダ、1066 CX
- 積極的、募集していない
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
-
Groningen、オランダ、9713 GZ
- 積極的、募集していない
- UMC Groningen
-
Nijmegen、オランダ、6525 GA
- 積極的、募集していない
- Stichting Radboud Universitair Medisch Centrum
-
Rotterdam、オランダ、3015 GD
- 積極的、募集していない
- Erasmus MC
-
-
-
-
-
Bankstown、オーストラリア、2200
- 積極的、募集していない
- Bankstown-Lidcombe Hospital
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア、6009
- 積極的、募集していない
- Sir Charles Gairdner Hospital
-
-
-
-
-
Calgary、カナダ、T2N 4N2
- 募集
- Tom Baker Cancer Center
-
Montreal、カナダ、HIT 2M4
- 積極的、募集していない
- Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 1Z2
- 募集
- Alberta Health Services Cross Cancer Institute
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Hospital
-
-
-
-
-
Lund、スウェーデン、22185
- 積極的、募集していない
- Skane University Hospital Lund
-
Solna、スウェーデン、171 76
- 積極的、募集していない
- Karolinska University Hospital
-
-
-
-
-
Barcelona、スペイン、08035
- 積極的、募集していない
- Hospital Universitario Vall d'Hebron
-
Barcelona、スペイン、08041
- 引きこもった
- Hospital de la Santa Creu i Sant Pau Barcelona
-
Barcelona、スペイン、08908
- 積極的、募集していない
- Institut Catala d'Oncologia - L'Hospitalet
-
El Palmar、スペイン、30120
- 引きこもった
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Madrid、スペイン、28041
- 積極的、募集していない
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28040
- 積極的、募集していない
- Hospital Clinico San Carlos
-
Madrid、スペイン、28007
- 積極的、募集していない
- Hospital General Universitario Gregorio Maranon
-
Madrid、スペイン、28040
- 積極的、募集していない
- Hospital Fundación Jiménez Díaz
-
Santiago de Compostela、スペイン、15706
- 積極的、募集していない
- Hospital Clinico Universitario de Santiago de Compostela
-
Seville、スペイン、41013
- 積極的、募集していない
- Hospital Universitario Virgen del Rocio
-
Zaragoza、スペイン、50009
- 引きこもった
- Hospital Universitario Miguel Servet
-
-
-
-
-
Brno、チェコ、65653
- 積極的、募集していない
- Masarykuv onkologicky ustav
-
Hradec Králové、チェコ、500 05
- 引きこもった
- Fakultni nemocnice Hradec Kralove
-
Olomouc、チェコ、77900
- 積極的、募集していない
- Fakultni nemocnice Olomouc - Oncology clinic
-
-
-
-
-
Santiago、チリ、7500921
- 積極的、募集していない
- Instituto Oncologico FALP
-
Santiago、チリ、7560908
- 積極的、募集していない
- Centro de Oncologia de Precision, Universidad Mayor
-
-
-
-
-
Aarhus、デンマーク、8200
- 積極的、募集していない
- Aarhus University Hospital
-
-
-
-
-
Bad Saarow、ドイツ、15526
- 積極的、募集していない
- Helios Klinikum Bad Saarow
-
Berlin、ドイツ、13125
- 積極的、募集していない
- Helios Klinikum Berlin-Buch
-
Essen、ドイツ、45147
- 積極的、募集していない
- Universitaetsklinikum Essen
-
Hamburg、ドイツ、20246
- 積極的、募集していない
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover、ドイツ、30625
- 積極的、募集していない
- Medizinische Hochschule Hannover- Urology Oncology
-
Mannheim、ドイツ、68167
- 積極的、募集していない
- Universitaetsmedizin Mannheim
-
-
-
-
-
Bergen、ノルウェー、5021
- 積極的、募集していない
- Haukeland University Hospital - Bergen
-
Oslo、ノルウェー、0310
- 積極的、募集していない
- Oslo University Hospital
-
-
-
-
-
Debrecen、ハンガリー、4032
- 積極的、募集していない
- Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
-
-
-
-
-
Bordeaux、フランス、33076
- 積極的、募集していない
- Institut Bergonie
-
Lille、フランス、59000
- 積極的、募集していない
- Centre Oscar Lambret
-
Lyon、フランス、69008
- 積極的、募集していない
- Centre Leon Berard
-
Marseille、フランス、13005
- 積極的、募集していない
- AP-HM - Hôpital de la Timone
-
Rennes、フランス、35042
- 積極的、募集していない
- Centre Eugene Marquis
-
Saint-Herblain、フランス、44800
- 積極的、募集していない
- ICO St-Herblain
-
Toulouse、フランス、31400
- 積極的、募集していない
- CHU de Toulouse - Hospital Rangueil
-
Villejuif、フランス、94805
- 積極的、募集していない
- Gustave Roussy
-
-
-
-
-
Campinas、ブラジル、130.83-888
- 積極的、募集していない
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
-
Rio de Janeiro、ブラジル、20.230-130
- 積極的、募集していない
- lnstituto Nacional de Cancer - INCA
-
São Paulo、ブラジル、09060-650
- 積極的、募集していない
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
-
-
-
Brzozów、ポーランド、36-200
- 積極的、募集していない
- Szpital Specjalistyczny w Brzozowie
-
Bydgoszcz、ポーランド、85-796
- 引きこもった
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka
-
Gliwice、ポーランド、44-102
- 積極的、募集していない
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
-
Warsaw、ポーランド、02-781
- 積極的、募集していない
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
-
-
-
-
-
Aguascalientes、メキシコ、20116
- 引きこもった
- Centro de Investigacion Medica Aquascalientes (CIMA)
-
Monterrey、メキシコ、64710
- 積極的、募集していない
- I Can Oncology Center SA De CV
-
Oaxaca City、メキシコ、68000
- 引きこもった
- Oaxaca Site Management Organization S.C.
-
-
-
-
-
Kaohsiung City、台湾、83301
- 積極的、募集していない
- Chang Gung Memorial Hospital - Kaohsiung Branch
-
New Taipei City、台湾、10002
- 積極的、募集していない
- National Taiwan University Hospital
-
Taichung、台湾、40447
- 積極的、募集していない
- China Medical University Hospital
-
Taipei、台湾、11217
- 積極的、募集していない
- Taipei Veterans General Hospital (VGHTP)
-
Taoyuan、台湾、33305
- 積極的、募集していない
- Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
-
-
-
-
-
Seoul、韓国、03080
- 積極的、募集していない
- Seoul National University Hospital
-
Seoul、韓国、06351
- 積極的、募集していない
- Samsung Medical Center
-
Seoul、韓国、08308
- 積極的、募集していない
- Korea University Guro Hospital
-
Seoul、韓国、05505
- 積極的、募集していない
- Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韓国、10408
- 引きこもった
- National Cancer Center
-
-
-
-
-
Central、香港
- 引きこもった
- Humanity & Health Clinical Trial Centre
-
Jordon、香港
- 積極的、募集していない
- Hong Kong United Oncology Centre
-
Shatin、香港
- 積極的、募集していない
- Prince of Wales Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
-
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
-
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
-
Participants must have received the following treatment:
- DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
- Part 1b: Treatment with ≥2 prior TKI for GISTs
- Part 2: Prior treatment with imatinib only
- GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
-
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
-
Eastern Cooperative Oncology Group (ECOG) Status
- 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
- 0 to 1 (GIST 1L Substudy)
-
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
- Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
- Clinically significant cardiac disease
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
- Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
- Any active bleeding excluding hemorrhoidal or gum bleeding
- Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
- Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
- Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
- Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1a
Bezuclastinib plus sunitinib 37.5 mg once a day (QD) |
Participants will receive bezuclastinib orally until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
実験的:Part 2 - Experimental Group
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
アクティブコンパレータ:Part 2 - Control Group
Sunitinib 37.5 mg QD |
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
実験的:Part 1b - DDI Cohort 1
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
実験的:Part 1b - DDI Cohort 2
Sunitinib 37.5 mg QD plus bezuclastinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
実験的:DDI Substudy (Midazolam)
Midazolam, bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. Participants will receive a single-dose of midazolam on Day 1 and Day 15 |
|
実験的:GIST 1L Substudy
Bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
他の名前:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
他の名前:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1a - pharmacokinetics - Cmax
時間枠:16 days
|
Maximum plasma concentration (Cmax) |
16 days
|
|
Part 1a - pharmacokinetics - AUC
時間枠:16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
Part 1b - pharmacokinetics - Cmax
時間枠:14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
|
Part 1b - pharmacokinetics - AUC
時間枠:14 days
|
Area under the plasma concentration-time curve (AUC) |
14 days
|
|
Part 1b - pharmacokinetics - Tmax
時間枠:14 days
|
Time to maximum observed plasma concentration (Tmax) |
14 days
|
|
Part 2 - Progression Free Survival (PFS)
時間枠:Approximately 48 months
|
Time from first dose to documented disease progression or death due to any cause, whichever occurs first |
Approximately 48 months
|
|
DDI Substudy - pharmacokinetics - AUC
時間枠:16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
DDI Substudy - pharmacokinetics - Cmax
時間枠:14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All Study Parts - observing the safety of each treatment regimen.
時間枠:Approximately 48 months
|
Incidence and severity of Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
時間枠:Approximately 48 months
|
Incidence and severity of Serious Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
時間枠:Approximately 48 months
|
Incidence of Adverse Events leading to dose modifications from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
時間枠:Approximately 48 months
|
Change from baseline in laboratory results |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
時間枠:Approximately 48 months
|
Time from first dose to death due to any cause |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
時間枠:Approximately 48 months
|
Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
時間枠:Approximately 48 months
|
Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks |
Approximately 48 months
|
|
Part 1a, Part 1b. Part 2 - Time to response (TTR)
時間枠:Approximately 48 months
|
Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
時間枠:Approximately 48 months
|
Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first |
Approximately 48 months
|
|
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
時間枠:Approximately 48 months
|
Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms. |
Approximately 48 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CGT9486-21-301
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。